A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Authors

Nancy L Bartlett, Washington University School of Medicine in St. Louis
et al.

Journal

Blood

Publication Date

11-19-2020

Volume

136

Issue

21

First Page

2401

Last Page

2409

Document Type

Open Access Publication

DOI

10.1182/blood.2019004701

Rights and Permissions

Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, Reeder C, Sher T, Chen R, Schwarz SE, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020 Nov 19;136(21):2401-2409. doi: 10.1182/blood.2019004701 This research was originally published in Blood Advances. © the American Society of Hematology.

Recommended Citation

Bartlett, Nancy L and et al., "A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma." Blood. 136, 21. 2401 - 2409. (2020).
https://digitalcommons.wustl.edu/oa_4/519